Originally published In Press as doi:10.1074/jbc.M208425200 on September 11, 2002
J. Biol. Chem., Vol. 277, Issue 49, 47325-47330, December 6, 2002
X-ray Structure of Two Crystalline Forms of a
Streptomycete Ribonuclease with Cytotoxic
Activity*
Jozef
Sevcik
§,
Lubica
Urbanikova
,
Peter A.
Leland¶
, and
Ronald T.
Raines¶**
From the
Institute of Molecular Biology, Slovak
Academy of Sciences, Dubravska cesta 21, 84251 Bratislava, Slovak
Republic, and the Departments of ¶ Biochemistry and
** Chemistry, University of Wisconsin-Madison, Madison,
Wisconsin 53706
Received for publication, August 18, 2002
 |
ABSTRACT |
Ribonuclease (RNase) Sa3 is secreted by the
Gram-positive bacterium Streptomyces aureofaciens. The
enzyme catalyzes the cleavage of RNA on the 3' side of guanosine
residues. Here, x-ray diffraction analysis was used to determine the
three-dimensional structure of two distinct crystalline forms of RNase
Sa3 to a resolution of 2.0 and 1.7 Å. These two structures are similar
to each other as well as to that of a homolog, RNase Sa. All of the key
active-site residues of RNase Sa (Asn42, Glu44,
Glu57, Arg72, and His88) are
located in the putative active site of RNase Sa3. Also herein, RNase
Sa3 is shown to be toxic to human erythroleukemia cells in culture.
Like onconase, which is an amphibian ribonuclease in Phase III clinical
trials as a cancer chemotherapeutic, RNase Sa3 is not inhibited by the
cytosolic ribonuclease inhibitor protein. Thus, a prokaryotic
ribonuclease can be toxic to mammalian cells.
 |
INTRODUCTION |
RNase Sa was the first ribonuclease to be isolated from the growth
medium of a Gram-positive microorganism, Streptomyces
aureofaciens (1). Streptomycete ribonucleases belong to
the prokaryotic subfamily of microbial ribonucleases of the T1 family,
which was identified by Hartley over twenty years ago (2). Amino acid sequence identity between Streptomycete ribonucleases and
barnase, the best characterized member of the family, is low. Yet,
their active sites have a similar structure (3).
After its amino acid sequence was determined (4), RNase Sa became the
object of intense structural studies designed to reveal its catalytic
mechanism (5-8) and conformational properties (9-12). The level of
the enzyme in its natural source is low, and its isolation is tedious.
Approaches using recombinant DNA were necessary to obtain adequate
quantities of RNase Sa. Consequently, genes encoding two RNase Sa
homologs, RNase Sa2 (13) and RNase Sa3 (14), were cloned from
S. aureofaciens strains R8/26 and CCM 3239, respectively.
Isolation of Sa ribonucleases after the expression of their genes in
Escherichia coli has not been successful. Apparently, the
enzymes are toxic to host cells despite their being directed for
secretion. Successful heterologous production has been achieved only by
the simultaneous expression of an Sa ribonuclease gene together with a
gene encoding barstar, a protein inhibitor from Bacillus
amyloliquefaciens (15). The yields range from 10 to 50 mg of
protein/liter of culture medium (16). Barstar inhibits the enzymatic
activity of Sa ribonucleases as it does barnase, its native partner, by
sterically blocking the active site (17, 18). Dissociation constants of
the complexes of RNase Sa, Sa2, and Sa3 with barstar are 2 × 10
10, 4 × 10
10, and 2 × 10
12 M, respectively. For comparison, the
dissociation constant for the barnase/barstar complex is
10
14 M (15).
The cytosol of mammalian cells contains a ribonuclease inhibitor
(RI)1 protein that binds
tightly to mammalian secretory ribonucleases (19, 20). The ability of
secretory ribonucleases from human (21), cow (22-24), bull (25-27),
and frog (28) to evade RI endows them with toxicity for
mammalian cells. These secretory ribonucleases from vertebrates are not
homologous to microbial ribonucleases. We suspected that a microbial
secretory ribonuclease, such as RNase Sa3, could likewise be toxic to
mammalian cells if its structure enables it to evade RI.
Here, we report the atomic structure of two crystalline forms for RNase
Sa3. We also report that RNase Sa3 does indeed have the ability to
evade RI and is cytotoxic for human erythroleukemia cells. Thus, RNase
Sa3 is a prokaryotic ribonuclease with demonstrable cytotoxic activity.
 |
EXPERIMENTAL PROCEDURES |
Protein Crystallization--
Protein production, purification,
and crystallization were performed as described previously (29). The
hanging-drop vapor-diffusion method was used to prepare two crystalline
forms. Trigonal crystals (crystal I) in the
P3121 space group with unit-cell dimensions of
a = b = 64.72 Å, c = 69.57 Å, and
= 120° were grown using 0.10 M Hepes buffer, pH 7.6, containing
Li2SO4 (1.6 M) as the precipitant
solution. Hanging drops consisted of 0.05 M Tris-HCl buffer, pH 8.2, containing protein (7.5 mg ml
1), Hepes
(0.05 M), and Li2SO4 (0.8 M). Tetragonal crystals (crystal II) in the
P41212 space group with unit-cell
dimensions of a = b = 34.05 Å and
c = 147.22 Å were grown using 2-methyl-2,4-pentanediol (10%, v/v) and ammonium sulfate (40 mM) as the precipitant
solution. Hanging drops consisted of 20 mM sodium acetate,
2 mM calcium acetate buffer, pH 4.2, containing protein (10 mg ml
1), 2-methyl-2,4-pentanediol (5%, v/v), and
ammonium sulfate (20 mM).
Crystallography Data Collection and Processing--
X-ray
diffraction data collection and processing were performed as described
previously (29). Data from crystal I were collected to 2.0 Å at 100 K
using synchrotron facilities at EMBL (Hamburg, Germany), and data from
crystal II were collected likewise to 1.7 Å at room temperature. Data
were processed with the HKL package (30). Data sets from both
crystalline forms were 100% complete with
Rmerge values of 6.0 and 3.6% for crystals I
and II, respectively.
Protein Structure Determination and
Refinement--
The structures from crystals I (structure I) and II
(structure II) were determined by molecular replacement using the
program AMoRe (31) and the structure of RNase Sa as a search model
(Protein Data Bank entry 1RGG). The initial model yielded for structure I an R-factor of 46% and a correlation coefficient of
51.7% for data at 10-3 Å. The initial model yielded for structure II
an R-factor of 47% and a correlation coefficient of 45.0%
for data at 10-3 Å. Molecular replacement showed clearly that
there was one protein molecule in the asymmetric unit in both
structures (29).
Individual atomic refinement was performed against 95% of the data by
using the maximum likelihood program REFMAC5 (version 4.1) from the
CCP4 package (32) against 95% of the data. The remaining 5% of the
data randomly excluded from the full data set by the program Uniqueify
from the CCP4 package was used for cross-validation by means of the
Rfree factor (33). The last refinement cycle was
carried out against all of the data. The Sparse Matrix method was used
for minimization. After each refinement cycle, the automated refinement
procedure ARP/wARP (34) was applied for modeling and updating the
solvent structure. The models were inspected against
3Fo
2Fc and
Fo
Fc maps and adjusted
manually between the cycles of refinement with the program O (35).
Both structures were refined with isotropic and, in later stages,
anisotropic temperature factors including contributions to the
structure factors from the hydrogen atoms, which were generated in
standard geometries. The inclusion of hydrogen atoms lowered the values
of R and Rfree by >1 unit. Isotropic
and anisotropic temperature factors, bond lengths, and bond angles were
restrained according to the standard criteria employed by REFMAC5.
Assay of Ribonuclease Inhibitor Binding--
Human ribonuclease
inhibitor (hRI) and RNase A were from Sigma. hRI was stored in 20 mM Hepes-KOH buffer, pH 7.6, containing glycerol (50%,
v/v), KCl (50 mM), and dithiothreitol (8 mM).
The effect of hRI on ribonucleolytic activity was measured as described previously (36) with minor modifications. RNase Sa3 was incubated with
hRI for 5 min at room temperature. The enzymatic reaction was initiated
at 37 °C by the addition of substrate. The reaction mixture (1.0 ml)
was 0.10 M sodium phosphate buffer, pH 7.5, containing a
ribonuclease (RNase Sa3, RNase Sa, or RNase A), hRI, yeast RNA (3 mg),
EDTA (1.0 mM), and dithiothreitol (5 mM). After
15 min, the enzymatic reaction was terminated by cooling the reaction mixture on ice for 2 min and then adding a solution (0.25 ml) of
uranylacetate (0.75% w/v) in aqueous perchloric acid (25% v/v). The
quenched reaction mixture was subjected to centrifugation, and the
supernatant was diluted by 25-fold with distilled water before
recording its absorbance at 260 nm. The concentration of ribonuclease
in the reaction mixture was adjusted to give an increase in absorbance
at 260 nm of 0.2-0.3 cm
1 in the absence of hRI.
Assay of Cytotoxicity--
Onconase (22) and RNase Sa3 (16) were
prepared as described previously. K-562 cells, which are from a
continuous human chronic myelogenous leukemia line, were from the
American Type Culture Collection (Manassas, VA). The effect of
ribonucleases on the proliferation of K-562 cells was determined by
measuring the incorporation of
[methyl-3H]thymidine into cellular DNA as
described previously (22, 37) with the exception that the stock
solution of ribonucleases was in 10 mM sodium phosphate
buffer, pH 8.0, containing NaCl (0.10 M). Data represent
the average of quadruplicate samples within an individual assay. The
IC50 value of each cytotoxic ribonuclease was calculated by
using the equation: S = 100 × IC50/(IC50 + [ribonuclease]) where
S is the percent of total DNA synthesis after the incubation period (24).
 |
RESULTS AND DISCUSSION |
Quality of Final Protein Structure Models--
The starting
R-factors in the refinement were 46.5% (48.3%) for
structure I (structure II). Refinement converged with R- and Rfree factors of 15.4% (18.6%) and
21.4% (22.4%), respectively. Both models have good geometry with
r.m.s. deviations from ideal bond lengths and angles of 0.021 Å (0.020 Å) and 1.831° (1.783°). 93.9% (93.6%) of the
and
dihedral angles were in the most favored region of the Ramachandran
plot (38) as calculated with the program Procheck (39). None of the
residues was in a disallowed region. For both structures, the
dispersion precision indicator (59, 60) based on the values of
R- and Rfree factors yields estimated
standard uncertainty (ESU) <0.19 and <0.13 Å, respectively. The
atomic coordinates of structure I and structure II of RNase Sa3 have
been deposited in the Protein Data Bank with accession codes 1MGW and
1MGR, respectively.
The crystallographic refinement and model statistics are
listed in Table I. The average
temperature factors for main-chain atoms for both structures as a
function of residue number are shown in Fig.
1. Surprisingly, the B-factors
are lower for structure II (room temperature data) than for structure I
(100 K data), which can be explained by the lower water content in
crystal forms II (34%) and I (68%). The average B-factors
agree well with estimates from the Wilson plot (61). The pattern of
variation is similar for both structures, but the amplitude of
variation is larger for structure II. The quality of the electron
density in the interior of both structures is approximately equal
despite the different resolutions and conditions for data
collection.
Description of Protein Structures--
Recombinant RNase Sa3
consists of 99 amino acid residues. The main secondary structure
elements are an
-helix (residues 18-28) and a three-stranded
antiparallel
-sheet (residues 55-61, 72-78, and 82-87). The
protein belongs to the Alpha Beta Roll group of the CATH
classification of protein domain structures (40). The final model
for structure I contains 782 protein atoms and 145 water
molecules. The final model for structure II contains 774 protein atoms
and 49 water molecules. The peptide bond preceding Pro30 is in the cis-conformation. The enzyme
contains two cysteine residues in positions 10 and 99, which form a
disulfide bond.
In structure I, all residues were built, and there are no residues with
alternative conformations. A difference electron density was seen after all refinement cycles in the middle of four water molecules arranged in the corners of a tetrahedron. A lithium cation
was modeled at the site of difference electron density and refined as
shown in Fig. 2A. The
distances to respective water molecules are 1.8-2.0 Å. The
B-factors of water molecules and the Li+ ion are
30-36 and 16 Å2, respectively.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2.
Three-dimensional structure of RNase
Sa3. A, electron density of lithium ion of RNase Sa3
structure I in the middle of a tetrahedron formed by four water
molecules. Putative hydrogen bonds are denoted by broken
lines. Ser34 is from a molecule related by symmetry.
B, electron density of sulfate anion of RNase Sa3 structure
II at the 1 level and putative hydrogen bonds with neighboring
residues. For clarity, electron density of the residues is omitted.
C, two views of the interaction of two adjacent RNase Sa3
molecules in structure I. D, contact region of four RNase
Sa3 molecules in structure II. For clarity, electron density at the
0.3 level for residues from only two molecules is shown.
E, superposition of RNase Sa (red) (8) and RNase
Sa3 structure I (green) based on 37 core C
atoms. Panels A, B, and D were
produced with the program Bobscript (57). Panels
C and E were produced with Molscript (58).
|
|
In structure II, residues Ala1, Ser2, and the
side chain of Val3 (which together form an N-terminal tail)
are missing, because there was no electron density clear enough to
model these residues. The electron density for Lys4 and
Trp79 side chains was poor, resulting in temperature
factors of up to 60 Å2. Alternative conformations were
built for the O
atom of Ser12. A sulfate
anion SO
was modeled at the putative
phosphoryl group binding site as shown in Fig. 2B in analogy
to one found in RNase Sa (8). The average S-O bond length was 1.45 Å.
The room temperature and low temperature structures are
almost identical. An overlap of the two structures based on the
minimization of distances between 94 C
atoms (excluding
the five N-terminal C
atoms) yields an r.m.s.
displacement of 0.50 Å with a maximum displacement of 1.75 Å at the
Trp79 side chain.
Crystal Packing and Lattice Interactions--
In structure I, each
molecule makes intermolecular contacts with three neighbors. The
crystal consists of a lattice of molecules that form continuous
parallel chains between those that are large channels of the solvent
corresponding to 68% crystal volume. Between each pair of chains,
every third molecule forms close intermolecular contacts with its
partner from the neighboring chain. As shown in Fig. 2C, the
N-terminal loops of two neighboring molecules are intertwined and
trapped between the two molecules, forming a number of contacts that
prevent disorder.
In structure II, each molecule makes intermolecular contacts with 12 neighboring molecules. The molecules are packed closely, which results
in a solvent content of only 34%. It is interesting to note that four
neighboring molecules in the crystal face each other with disordered
regions. As shown in Fig. 2D, this interface contains
N-terminal residues of two molecules and Trp79 residues of
two other molecules. The disorder of these regions is surprising as the
space in the interface does not seem to be large enough to allow for
substantial atomic motion.
Comparison with Other Ribonuclease Structures--
Sa
ribonucleases catalyze the cleavage of the P-O5' bonds of
single-stranded RNA on the 3' side of guanosine nucleotides (62). The
most thoroughly studied Streptomycete ribonuclease is RNase Sa, the structure of which was determined at various resolutions, including atomic. As shown in Fig. 3, a
comparison of the amino acid sequences of RNase Sa and RNase Sa3
reveals that there are 67 identical residues (69% identity), 17 of
which are conserved in all enzymes belonging to the
prokaryotic subfamily of microbial ribonucleases. There are five key
residues: Asn42, Glu44, Glu57,
Arg72, and His88 (Sa3 numbering) that are
conserved strictly in all microbial ribonucleases of the T1 family. By
analogy, Glu57 and His88 participate in general
acid base catalysis. Glu44 and Arg72
participate in nucleobase and phosphoryl group binding, respectively. The side chain of Asn42 plays an important role in
stabilizing the main-chain loop that forms the binding site for the
nucleobase of a substrate. Replacing an equivalent asparagine residue
in RNase Sa with aspartate, alanine, or
serine decreases the conformational
stability of the enzyme by 1.5-2.3 kcal/mol (9) and decreases the
catalytic activity by 85%.2 The N39S variant of
RNase Sa also shows unexpected changes in structure (Protein Data Bank
code 1BOX).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Amino acid sequences of RNase Sa3 and RNase
Sa. Residues conserved in all microbial ribonucleases are denoted
by " ," and those conserved in the prokaryotic subfamily are
denoted by an asterisk.
|
|
An overlap of RNase Sa3 structure I with the structure of RNase Sa
based on minimization of distances between those corresponding C
atoms that form the core of the molecules (37 atoms)
yields an r.m.s. deviation of 0.35 Å and a maximum deviation of 0.84 Å, which is the distance between the C
atoms of
Gly28 (Sa3) and Asp25 (Sa). This superposition
reveals a high degree of similarity as depicted in Fig. 2E.
Differences in the main-chain fold are seen only at the N and C termini
and reached 5 and 2 Å, respectively. The N-terminal residues of RNase
Sa are well determined as they are laid on the surface of the molecule.
The situation is different in RNase Sa3 in which the N-terminal
residues form a tail that does not contact the remainder of the
molecule but instead points to the solution.
Ribonuclease Inhibitor Binding--
Previously, the ribonuclease
inhibitor protein was demonstrated to have no effect on the
ribonucleolytic activity of microbial ribonucleases T1 and U1 (41). In
the conditions used herein, hRI was able to fully inactivate RNase A
but had no effect on the activity of RNase Sa and Sa3, even at a
10-fold greater concentration. Thus, streptomycete ribonucleases Sa and
Sa3 bind tightly to barstar (15) but evade hRI.
Cytotoxicity--
RNase Sa3 exhibits dose-dependent
toxicity to K-562 cells as shown in Fig.
4. The IC50 value for RNase
Sa3 is (5 ± 1) µM, which is only 10-fold greater
than that of onconase. In contrast to RNase Sa3, RNase Sa does not
exhibit significant cytotoxic activity.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of onconase, RNase Sa3, and RNase Sa
on the proliferation of K-562 cells. Cell proliferation was
measured by incorporation of
[methyl-3H]thymidine into cellular DNA after a
48-h incubation at 37 °C with a ribonuclease. Each value is the mean
(±S.E.) of at least three independent experiments with triplicate
samples and is expressed as a percentage of the control, which lacked a
ribonuclease. IC50 values are 0.43 ± 0.04 µM (onconase), 5 ± 1 µM (RNase Sa3),
and >35 µM (RNase Sa).
|
|
Ribonucleases can be cytotoxic by virtue of their ribonucleolytic
activity. The cytotoxic activity of some vertebrate ribonucleases has
led to their development as cancer chemotherapeutics (42-44). For
example, onconase, which is the homolog of RNase A in the Northern
leopard frog (Rana pipiens), is now in Phase III clinical trials for the treatment of malignant mesothelioma, a form of lung
cancer (45). A few fungal ribonucleases are also known to have
antitumor activity (46). Specifically, the Aspergillus ribonucleases
-sarcin (47), mitogillin (48), restrictocin (49), and
Asp-fl (50) kill cells by cleaving a specific phosphodiester bond in 28 S rRNA, thereby disrupting the ribosome and impairing protein
biosynthesis (51).
To our knowledge, RNase Sa3 is only the second prokaryotic ribonuclease
to have demonstrable cytotoxic activity (63). The mechanism by which
RNase Sa3 manifests its cytotoxicity is unclear but probably relies on
its ribonucleolytic activity as does the cytotoxicity of other
ribonucleases (52). The three-dimensional structure of RNase Sa3, which
is highly similar to that of its non-toxic homolog RNase Sa (Fig.
2E), provides no obvious clues. Likewise, the conformational
stability of the two ribonucleases, which can correlate with
cytotoxicity (53), is similar (11). However, the endogenous ability of
RNase Sa3 to evade RI is reminiscent of that of onconase (28) and
bovine seminal ribonuclease (54), two mammalian ribonucleases with
cytotoxic activity. This ability is also probably critical for the
cytotoxicity of RNase Sa3. Furthermore, RNase Sa3 is more cationic than
is RNase Sa (pI = 5.4 and 3.5, respectively) (16), and more
cationic ribonucleases are more cytotoxic (55). Additional studies are
necessary to reveal the basis as well as the mechanism of RNase Sa3
cytotoxicity. These studies are compelled by the need to develop new
cytotoxins for use in cell biology and medicine (43, 56).
 |
ACKNOWLEDGEMENTS |
We are grateful to C. N. Pace for
contributive discussions. We thank EMBL in Hamburg for providing
facilities on beamlines X31 and BW7A. J. Sevcik and L. Urbanikova thank the European Community for support through the Access
to Research Infrastructure Action of the Improving Human Potential
Program to the EMBL Hamburg Outstation (contract number
HPRI-CT-1999-00017).
 |
FOOTNOTES |
*
This work was supported in part by Howard Hughes Medical
Institute Grant 75195-547601, Slovak Academy of Sciences Grant
2/1018/21, and National Institutes of Health Grant CA73808.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1MGW and 1MGR) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
§
To whom correspondence may be addressed. Tel.: 42-125-930-7435;
Fax: 42-125-930-7416; E-mail: umbisevc@savba.sk.
Supported by Molecular Biosciences Training Grant T32 GM07215
from the National Institutes of Health and a Steenbock/Wharton fellowship from the Department of Biochemistry at the University of
Wisconsin-Madison.

To whom correspondence may be addressed: Dept. of Biochemistry,
University of Wisconsin-Madison, 433 Babcock Dr., Madison, WI
53706-1544. Tel.: 608-262-8588; Fax: 608-262-3453; E-mail: raines@biochem.wisc.edu.
Published, JBC Papers in Press, September 11, 2002, DOI 10.1074/jbc.M208425200
2
L. Urbanikova, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
RI, ribonuclease
inhibitor;
hRI, human ribonuclease inhibitor;
r.m.s., root mean
square.
 |
REFERENCES |
| 1.
|
Bacova, M.,
Zelinkova, E.,
and Zelinka, J.
(1971)
Biochim. Biophys. Acta
235,
335-338[Medline]
[Order article via Infotrieve]
|
| 2.
|
Hartley, R. W.
(1980)
J. Mol. Evol.
15,
355-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Sevcik, J.,
Sanishvili, R. G.,
Pavlovsky, A. G.,
and Polyakov, K. M.
(1990)
Trends Biochem. Sci.
15,
158-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Shlyapnikov, S. V.,
Both, V.,
Kulikov, V. A.,
Dementiev, A. A.,
Sevcik, J.,
and Zelinka, J.
(1986)
FEBS Lett.
209,
335-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sevcik, J.,
Dodson, E. J.,
and Dodson, G. G.
(1991)
Acta Crystallogr. B
47,
240-253
|
| 6.
|
Sevcik, J.,
Hill, C. P.,
Dauter, Z.,
and Wilson, K. S.
(1993)
Acta Crystallogr. D
49,
257-271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Sevcik, J.,
Zegers, I.,
Wyns, L.,
Dauter, Z.,
and Wilson, K. S.
(1993)
Eur. J. Biochem.
216,
301-305[Medline]
[Order article via Infotrieve]
|
| 8.
|
Sevcik, J.,
Dauter, Z.,
Lamzin, V. S.,
and Wilson, K. S.
(1996)
Acta Crystallogr. D
52,
327-344
|
| 9.
|
Hebert, E. J.,
Giletto, A.,
Sevcík, J.,
Urbániková, L.,
Wilson, K. S.,
Dauter, Z.,
and Pace, C. N.
(1998)
Biochemistry
37,
16192-16200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Pace, C. N.,
Alston, R. W.,
and Shaw, K. L.
(2000)
Protein Sci.
9,
1395-1398[Abstract]
|
| 11.
|
Pace, C. N.,
Horn, G.,
Hebert, E. J.,
Bechert, J.,
Shaw, K.,
Urbanikova, L.,
Scholtz, J. M.,
and Sevcik, J.
(2001)
J. Mol. Biol.
312,
393-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Shaw, K. L.,
Grimsley, G. R.,
Yakovlev, G. I.,
Makarov, A. A.,
and Pace, C. N.
(2001)
Protein Sci.
10,
1206-1215[Abstract/Free Full Text]
|
| 13.
|
Nazarov, V.
(1991)
Cloning the genes coding for extracellular ribonuclease and its inhibitor from Streptomyces aureofaciens, Ph.D. thesis,
, Institute of Molecular Biology, Bratislava, Slovak Republic
|
| 14.
|
Homerova, D.,
Hollanderova, Z.,
Kormanec, J.,
and Sevcik, J.
(1992)
Gene (Amst.)
119,
147-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Hartley, R. W.,
Both, V.,
Hebert, E. J.,
Homerova, D.,
Jucovic, M.,
Nazarov, V.,
Rybajlak, I.,
and Sevcik, J.
(1996)
Protein Pept. Lett.
4,
225-231
|
| 16.
|
Hebert, E. J.,
Grimsley, G. R.,
Hartley, R. W.,
Horn, G.,
Schell, D.,
Garcia, S.,
Both, V.,
Sevcik, J.,
and Pace, C. N.
(1997)
Protein Expression Purif.
11,
162-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Sevcik, J.,
Urbanikova, L.,
Dauter, Z.,
and Wilson, K. S.
(1998)
Acta Crystallogr. D
54,
954-963[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Urbanikova, L.,
and Sevcik, J.
(1998)
Acta Crystallogr. D
54,
403-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hofsteenge, J.
(1997)
in
Ribonucleases: Structures and Functions
(D'Alessio, G.
, and Riordan, J. F., eds)
, pp. 621-658, Academic Press, New York
|
| 20.
|
Shapiro, R.
(2001)
Methods Enzymol.
341,
611-628[Medline]
[Order article via Infotrieve]
|
| 21.
|
Leland, P. A.,
Staniszewski, K. E.,
Kim, B.-M.,
and Raines, R. T.
(2001)
J. Biol. Chem.
276,
43095-43102[Abstract/Free Full Text]
|
| 22.
|
Leland, P. A.,
Schultz, L. W.,
Kim, B.-M.,
and Raines, R. T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
98,
10407-10412
|
| 23.
|
Bretscher, L. E.,
Abel, R. L.,
and Raines, R. T.
(2000)
J. Biol. Chem.
275,
9893-9896[Abstract/Free Full Text]
|
| 24.
|
Haigis, M. C.,
Kurten, E. L.,
Abel, R. L.,
and Raines, R. T.
(2002)
J. Biol. Chem.
277,
11576-11581[Abstract/Free Full Text]
|
| 25.
|
Cafaro, B., De,
Lorenzo, C.,
Piccoli, R.,
Bracale, A.,
Mastronicola, M. R., Di,
Donato, A.,
and D'Alessio, G.
(1995)
FEBS Lett.
359,
31-34[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Kim, J.-S.,
Soucek, J.,
Matousek, J.,
and Raines, R. T.
(1995)
J. Biol. Chem.
270,
10525-10530[Abstract/Free Full Text]
|
| 27.
|
Matousek, J.,
Kim, J.-S.,
Soucek, J.,
Rihà, J.,
Ribò, M.,
Leland, P. A.,
and Raines, R. T.
(1997)
Comp. Biochem. Physiol.
118B,
881-888[CrossRef]
|
| 28.
|
Wu, Y.,
Mikulski, S. M.,
Ardelt, W.,
Rybak, S. M.,
and Youle, R. J.
(1993)
J. Biol. Chem.
268,
10686-10693[Abstract/Free Full Text]
|
| 29.
|
Hlinkova, V.,
Urbanikova, L.,
Krajcikova, D.,
and Sevcik, J.
(2001)
Acta Crystallogr. D
57,
737-739[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326
|
| 31.
|
Navaza, J.,
and Saludjian, P.
(1997)
Methods Enzymol.
276,
581-619
|
| 32.
|
Collaborative Computational Project Number 4.
(1994)
Acta Crystallogr. D
50,
760-763[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Brünger, A. T.
(1993)
Acta Crystallogr. D
49,
24-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Perrakis, A.,
Morris, R. M.,
and Lamzin, V. S.
(1999)
Nat. Struct. Biol.
6,
458-463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Jones, T. A.,
Zou, J. Y.,
Cowan, S. W.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. A
47,
110-119
|
| 36.
|
Egami, F.,
Takahashi, K.,
and Uchida, T.
(1964)
Prog. Nucleic Acid Res. Mol. Biol.
3,
59-101[Medline]
[Order article via Infotrieve]
|
| 37.
|
Leland, P. A.,
Staniszewski, K. E.,
Kim, B.-M.,
and Raines, R. T.
(2000)
FEBS Lett.
477,
203-207[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Ramakhrisnan, C.,
and Ramachandran, G. M.
(1965)
Biophys. J.
5,
909-933
|
| 39.
|
Laskowski, R. A.,
MacArthur, M. W.,
Moss, D. S.,
and Thornton, J. M.
(1993)
J. Appl. Crystallogr.
26,
283-291[CrossRef]
|
| 40.
|
Orengo, C. A.,
Michie, A. D.,
Jones, S.,
Jones, B. T.,
Swindells, M. B.,
and Thornton, J. M.
(1997)
Structure
5,
1093-1108[Medline]
[Order article via Infotrieve]
|
| 41.
|
Cho, S.,
and Joshi, J. G.
(1989)
Anal. Biochem.
176,
175-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Youle, R. J.,
and D'Alessio, G.
(1997)
in
Ribonucleases: Structures and Functions
(D'Alessio, G.
, and Riordan, J. F., eds)
, pp. 491-514, Academic Press, New York
|
| 43.
|
Leland, P. A.,
and Raines, R. T.
(2001)
Chem. Biol.
8,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Matousek, J.
(2001)
Comp. Biochem. Physiol. C Toxicol. Pharmacol.
129,
175-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Mikulski, S. M.,
Costanzi, J. J.,
Vogelzang, N. J.,
McCachren, S.,
Taub, R. N.,
Chun, H.,
Mittelman, A.,
Panella, T.,
Puccio, C.,
Fine, R.,
and Shogen, K.
(2002)
J. Clin. Oncol.
20,
274-281[Abstract/Free Full Text]
|
| 46.
|
Wool, I. G.
(1997)
in
Ribonucleases: Structures and Functionsv
(D'Alessio, G.
, and Riordan, J. F., eds)
, pp. 131-162, Academic Press, New York
|
| 47.
|
Pérez-Cañadillas, J. M.,
Santoro, J.,
Campos-Olivas, R.,
Lacadena, J.,
Martínez del Pozo, A.,
Gavilanes, J. G.,
Rico, M.,
and Bruix, M.
(2000)
J. Mol. Biol.
299,
1061-1073[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Kao, R.,
and Davies, J.
(1999)
J. Biol. Chem.
274,
12576-12582[Abstract/Free Full Text]
|
| 49.
|
Yang, X.,
and Moffat, K.
(1996)
Structure
4,
837-852[Medline]
[Order article via Infotrieve]
|
| 50.
|
Madan, T.,
Arora, N.,
and Sarma, P. U.
(1997)
Mol. Cell. Biochem.
175,
21-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Schindler, D. G.,
and Davies, J. E.
(1977)
Nucleic Acids Res.
4,
1097-1100[Abstract/Free Full Text]
|
| 52.
|
Kim, J.-S.,
Soucek, J.,
Matousek, J.,
and Raines, R. T.
(1995)
Biochem. J.
308,
547-550
|
| 53.
|
Klink, T. A.,
and Raines, R. T.
(2000)
J. Biol. Chem.
275,
17463-17467[Abstract/Free Full Text]
|
| 54.
|
Murthy, B. S.,
and Sirdeshmukh, R.
(1992)
Biochem. J.
281,
343-348
|
| 55.
|
Futami, J.,
Maeda, T.,
Kitazoe, M.,
Nukui, E.,
Tada, H.,
Seno, M.,
Kosaka, M.,
and Yamada, H.
(2001)
Biochemistry
26,
7518-7524[CrossRef]
|
| 56.
|
Rappuoli, R.,
and Montecucco, C.
(1997)
Guidebook to Protein Toxins and Their Use in Cell Biology
, Oxford University Press, New York
|
| 57.
|
Esnouf, R. M.
(1999)
Acta Crystallogr. D
55,
938-940[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Kraulis, P. J.
(1991)
J. Appl. Crystallogr.
24,
946-950[CrossRef]
|
| 59.
|
Cruickshank, D. W. J.
(1996)
in
Proceedings of the CCP4 Study Weekend, Macromolecular Refinement
(Dodson, E.
, Moore, M.
, Ralph, A.
, and Bailey, S., eds)
, pp. 11-22, SERC Daresbury Laboratory, Warrington, United Kingdom
|
| 60.
|
Murshudov, G. N.,
and Dodson, E. J.
(1997)
CCP4 Newslett. Protein Crystallogr.
33,
31-39
|
| 61.
|
Wilson, A. J. C.
(1942)
Nature
150,
151-152
|
| 62.
|
Zelinkova, E.,
Bacova, M.,
and Zelinka, J.
(1971)
Biochim. Biophys. Acta
235,
343-352[Medline]
[Order article via Infotrieve]
|
| 63.
|
Ilinskaya, O.,
Decker, K.,
Koshinski, A.,
Dreyer, F.,
and Repp, H.
(2001)
Toxicology
156,
101-107[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. W. Alston, L. Urbanikova, J. Sevcik, M. Lasagna, G. D. Reinhart, J. M. Scholtz, and C. N. Pace
Contribution of Single Tryptophan Residues to the Fluorescence and Stability of Ribonuclease Sa
Biophys. J.,
December 1, 2004;
87(6):
4036 - 4047.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.